Haemonetics (HAE) FY2016 results: revenue $909 million, down 0.2% on the year
Haemonetics Corp. (HAE) reported revenue of $909 million for fiscal 2016, the year ended 2 April 2016, down 0.2% on the year before. Net income was -$56 million, and diluted earnings per share $-1.09. The figures are the company's own, from the 10-K it filed with the SEC on 1 June 2016.
Revenue
$909 million
-0.2% on the year
FY2009FY2016
Operating margin
-4.8%
4.5% a year earlier
FY2009FY2016
Net income
-$56 million
FY2009FY2016
Diluted EPS
-$1.09
FY2009FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
909
910
939
-0.2%
Cost of revenue
503
476
470
+5.7%
Gross profit
406
434
468
-6.6%
Gross margin
44.7%
47.7%
49.9%
Research and development
45.0
54.2
54.2
-17.0%
Selling, general and administrative
317
337
366
-5.9%
Operating income
-43.9
40.5
46.4
Operating margin
-4.8%
4.5%
4.9%
Pre-tax income
-53.4
31.2
36.4
Income tax
2.2
14.3
1.3
-84.8%
Effective tax rate
n/a
45.8%
3.4%
Net income
-55.6
16.9
35.1
Net margin
-6.1%
1.9%
3.7%
Diluted EPS
-$1.09
$0.32
$0.67
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
122
127
140
-4.2%
Capital expenditure
102
122
73.6
-16.2%
Free cash flow
19.5
5.0
65.9
+292.5%
Free cash flow margin
2.1%
0.5%
7.0%
Cash from investing
-105
-122
-106
Cash from financing
-62.6
-33.2
-20.7
Depreciation and amortisation
89.9
86.1
81.7
+4.5%
Share-based compensation
6.9
14.1
13.1
-50.7%
Buybacks
61.0
39.0
0.0
+56.2%
Diluted shares, weighted
51m
52m
52m
-2.3%
Shares outstanding at period end
51m
52m
52m
-1.4%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
722
826
838
-12.7%
Short-term borrowings
n/a
n/a
0.0
Debt
408
430
440
-5.1%
Other liabilities
189
229
236
-17.4%
Total liabilities and equity
1,319
1,485
1,514
-11.2%
Fixed assets
338
322
271
+4.9%
Goodwill
268
334
337
-19.9%
Intangible assets
204
245
271
-16.4%
Cash and equivalents
115
161
192
-28.3%
Receivables
157
146
165
+7.7%
Inventory
187
211
198
-11.4%
Other assets
50.0
67.0
80.1
-25.5%
Total assets
1,319
1,485
1,514
-11.2%
10-K for the year ended 2 April 2016, filed 1 June 2016: the filing.